新诊断KMT2A重排急性髓系白血病的特征与预后:ECLA多中心研究
该多中心研究纳入490例新诊断KMT2A重排AML患者,分析融合亚型、共突变及治疗对预后的影响。中位随访42.6个月,中位OS为30.9个月,3年OS率49.9%。Ven+IC方案CRc率最高(89.5%),中位OS未达到;多因素分析显示MRD阴性、allo-HSCT及Ven+IC为EFS独立有利因素,KMT2A::MLLT4和EVI1过表达为独立不利因素。
要点
- KMT2A::MLLT3最常见(31.6%),KMT2A::MLLT4预后较差
- Ven+IC的CRc率89.5%,中位OS未达到,优于其他方案
- MRD阴性、allo-HSCT及Ven+IC为EFS独立有利因素
核心结论
- KMT2A::MLLT4融合及EVI1过表达是EFS的独立不利因素。
- MRD阴性、allo-HSCT及Ven+IC是EFS的独立有利因素。
研究设计与样本
- 多中心研究纳入华东白血病联盟2013年3月至2025年8月490例新诊断KMT2Ar AML患者。
- 中位随访时间42.6个月。
主要发现
- KMT2A::MLLT3最常见(31.6%),其次为KMT2A::MLLT4(25.1%)、KMT2A::ELL(20%)、KMT2A::MLLT10(12.7%)。
- 常见共突变包括KRAS(20.1%)、NRAS(19.0%)、TET2(10.2%)、WT1(8.6%)、PTPN11(7.4%)。
- 全部患者中位OS为30.9个月,3年OS率为49.9%。
关键数值与推荐
- Ven+IC组CRc率89.5%,IC组62.4%,Ven+减低强度化疗组57.3%,减低强度化疗组61.4%。
- Ven+IC组中位OS未达到,IC组39.9个月,Ven+减低强度化疗组34.8个月,减低强度化疗组12.7个月。
临床怎么用
- 对新诊断KMT2Ar AML应识别KMT2A::MLLT4融合及EVI1过表达等高危因素。
- 诱导后MRD阴性、接受allo-HSCT及Ven+IC与更优EFS相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acute myeloid leukemia (AML) harboring KMT2A rearrangement (KMT2Ar) was generally associated with poor prognosis. We enrolled 490 patients with KMT2Ar from the East China Leukemia Alliance between March 2013 and August 2025. KMT2A::MLLT3 was the most frequent KMT2Ar (31.6%), followed by KMT2A::MLLT4 (25.1%), KMT2A::ELL (20%), and KMT2A::MLLT10 (12.7%). KMT2A::MLLT4 showed an inferior prognosis. The most co-occurring gene mutations were KRAS (20.1%), NRAS (19.0%), TET2 (10.2%), WT1 (8.6%), and PTPN11 (7.4%). Trisomy 8 was more common in patients < 60 years, while FLT3-ITD was only detected in patients < 60 years. With a median follow-up time of 42.6 months, the median overall survival (OS) of all patients was 30.9 months, and the 3-year OS rate was 49.9%. Patients treated with venetoclax plus intensive chemotherapy (Ven+IC) showed the best composite complete remission (CRc) rate and OS compared to intensive chemotherapy, venetoclax plus reduced-intensive chemotherapy, and reduced-intensive chemotherapy (CRc rate: 89.5% vs. 62.4% vs. 57.3% vs. 61.4%; median OS: not reached vs. 39.9 months vs. 34.8 months vs. 12.7 months). Multivariate analysis identified multiparameter flow cytometry minimal residual disease negativity post-induction therapy, allogeneic hematopoietic stem cell transplantation, and Ven+IC as independent favorable prognostic factors for event-free survival (EFS), and KMT2A::MLLT4 fusion, EVI1 overexpression were independent unfavorable prognostic factors for EFS. In summary, our study showed characteristics and prognostic implications in newly diagnosed KMT2Ar AML in China.
引用
- Pan J, Fu C, Ling Q, et al. Characteristics and Prognostic Implications in Newly Diagnosed KMT2Ar AML: A Multicenter Study of the ECLA Group. Am J Hematol. 2026. PMID: 42187108. doi:10.1002/ajh.70377
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。